You are here

Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequ

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43HL121909-01
Agency Tracking Number: R43HL121909
Amount: $242,066.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NHLBI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
GEORGIA BIOBUSINESS CTR
ATHENS, GA 30602-1514
United States
DUNS: 95542358
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 RICHARD SHIMKETS
 (706) 542-7889
 rick.shimkets@abeomecorp.com
Business Contact
 RICHARD SHIMKETS
Phone: (706) 542-7889
Email: rick.shimkets@abeomecorp.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): We have developed and completed a proof-of-principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to ovalbumin injection using surface antibody capture and next-generation DNA sequencing technologies. A more commercially valuable proof is now sought using a novel screening method with an emerging drug target for hypercholesterolemia, known as PCSK9. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Therapeutic and diagnostic applications of monoclonal antibodies (mAbs) offer a way to target treatments to specific proteins. However, monoclonal antibodies have traditionally been made using hybridoma technologies which only access a small fraction ofthe immune system. Abeome has developed a novel method of antibody discovery using next-generation DNA sequencing of the variable gene repertoire of antigen-specific antibody producing cells. Thus, the immediate goal for this Phase I project is to us

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government